Clinical Trial

Pancreatic Cancer Clinical Trial 20193054

[LCID Study Number: 20193054]

A Randomized, Double-blind, and Placebo Controlled Multicenter Phase II Trial Evaluating Anamorelin in the Prevention of Cancer Induced-Weight Loss and Anorexia in Patients Receiving First-line Treatment of Advanced Pancreatic Cancer

The purpose of this study is to evaluate the effect of anamorelin on weight gain and anorexia symptoms in subjects with pancreatic ductal adenocarcinoma.

Disease/Condition: Pancreatic Cancer

Department: Hematology and Oncology

Location(s): Lahey Hospital & Medical Center (Burlington)

Primary Contact Email:

Primary Contact Phone: 781-744-3421

Clinical Trial Details

View NCT ID 04844970 on

Protocol #: 20193054

Principal Investigator(s): Francis W. Nugent III

Study Coordinator(s): Amy Wollenhaupt

Trial Phase: Investigator Initiated Study Phase 2